mcc-555 has been researched along with Alloxan Diabetes in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Foster, JR; Pickavance, LC; Widdowson, PS; Wilding, JP; Williams, G | 1 |
| Ishii, S; Tanaka, H; Upton, R; Widdowson, PS; Williams, G | 1 |
| Kadowaki, T | 1 |
1 review(s) available for mcc-555 and Alloxan Diabetes
| Article | Year |
|---|---|
[Insulin-sensitizing agents].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Isoxazoles; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
2 other study(ies) available for mcc-555 and Alloxan Diabetes
| Article | Year |
|---|---|
Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and beta-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat.
Topics: Animals; Apoptosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Administration Schedule; Insulin; Islets of Langerhans; Male; Nitric Oxide Synthase; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones | 2003 |
Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Topics: Animals; Basal Metabolism; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Fatty Acids; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver Glycogen; Male; Obesity; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Treatment Outcome; Triglycerides | 1998 |